Inhaled Insulin (Exubera) and Lung Cancer
April 9, 2008
Pfizer is updating the warnings section of the inhaled insulin product labeling to include new information regarding lung malignancies. During clinical trials, 6 patients treated with inhaled insulin had newly diagnosed lung malignancies compared to 1 patient in the control group. Additionally, there is 1 post-marketing report of a lung malignancy in a patient treated with inhaled insulin. All patients had a history of smoking and the company does not have sufficient data to determine if the malignancies are due to the inhaled insulin product.
In October, 2007 Pfizer discontinued inhaled insulin due to business reasons, although a small number of patients may be using the product.
Additional information is available at the following links:
- FDA MedWatch alert:
- Dear Healthcare Professional Letter:
- Dear Patient Letter:
April 9, 2008; University of Utah, Drug Information Service. Copyright 2009, Drug Information Service, University of Utah, Salt Lake City, UT.